Diversified Trust Co Takes Position in Surmodics, Inc. (NASDAQ:SRDX)


Share on StockTwits

Diversified Trust Co purchased a new stake in Surmodics, Inc. (NASDAQ:SRDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 4,796 shares of the company’s stock, valued at approximately $209,000.

Several other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Surmodics by 0.4% in the 2nd quarter. Vanguard Group Inc. now owns 914,213 shares of the company’s stock valued at $39,530,000 after buying an additional 3,535 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Surmodics by 7.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 88,650 shares of the company’s stock valued at $3,834,000 after buying an additional 6,199 shares during the period. Nuveen Asset Management LLC grew its stake in shares of Surmodics by 1.7% in the 2nd quarter. Nuveen Asset Management LLC now owns 70,802 shares of the company’s stock valued at $3,062,000 after buying an additional 1,164 shares during the period. Sei Investments Co. grew its stake in shares of Surmodics by 5.7% in the 2nd quarter. Sei Investments Co. now owns 64,693 shares of the company’s stock valued at $2,797,000 after buying an additional 3,465 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Surmodics by 18.5% in the 3rd quarter. Wells Fargo & Company MN now owns 41,238 shares of the company’s stock valued at $1,605,000 after buying an additional 6,436 shares during the period. 89.76% of the stock is owned by institutional investors and hedge funds.

Separately, BidaskClub raised shares of Surmodics from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $66.67.

In other Surmodics news, CEO Gary R. Maharaj sold 2,000 shares of the stock in a transaction that occurred on Monday, January 4th. The shares were sold at an average price of $43.96, for a total transaction of $87,920.00. Following the sale, the chief executive officer now directly owns 145,142 shares in the company, valued at approximately $6,380,442.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Joseph J. Stich sold 2,500 shares of the stock in a transaction that occurred on Tuesday, January 5th. The stock was sold at an average price of $45.00, for a total transaction of $112,500.00. Following the sale, the senior vice president now owns 50,562 shares in the company, valued at $2,275,290. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Shares of SRDX stock opened at $45.10 on Thursday. The firm’s 50 day moving average price is $40.57 and its 200-day moving average price is $41.64. Surmodics, Inc. has a one year low of $22.06 and a one year high of $49.00. The firm has a market cap of $617.06 million, a P/E ratio of 80.54, a P/E/G ratio of 67.83 and a beta of 0.98.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). Surmodics had a return on equity of 7.49% and a net margin of 7.39%. The company had revenue of $22.54 million during the quarter, compared to analyst estimates of $21.67 million. Analysts forecast that Surmodics, Inc. will post 0.31 EPS for the current fiscal year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics.

Read More: What are defining characteristics of a correction?

Want to see what other hedge funds are holding SRDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surmodics, Inc. (NASDAQ:SRDX).

Institutional Ownership by Quarter for Surmodics (NASDAQ:SRDX)

Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.